Company: GRCE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001140361-25-041804
Chunk: 4

Company: Grace Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Item 8
Chunk 4
---

      (Level 3)

      $ 
      $ 
      $ 
      $ 

      Assets

      Treasury bills classified as cash equivalents
     
      14,969 
      14,969 
       —  
       —  

      Total assets
     
      14,969 
      14,969 
       —  
       —  

      Liabilities

      Derivative warrant liabilities
     
      201 
       —  
       —  
      201 

      Total liabilities
     
      201 
       —  
       —  
      201 

   Assets and liabilities measured at fair value on a recurring basis as of March 31, 2025 are as follows:  

      Total

      Quoted prices

      in active markets

      (Level 1)

      Significant other

      observable inputs

      (Level 2)

      Significant

      unobservable inputs

      (Level 3)

      $ 
      $ 
      $ 
      $ 

      Assets

      Treasury bills classified as cash equivalents
     
      21,304 
      21,304 
       —  
       —  

      Total assets
     
      21,304 
      21,304 
       —  
       —  

      Liabilities

      Derivative warrant liabilities
     
      1,141 
       —  
       —  
      1,141 

      Total liabilities
     
      1,141 
       —  
       —  
      1,141 

   There were no changes in valuation techniques or transfers between Levels 1, 2 or 3 during the six months ended September 30, 2025. The Company’s derivative warrant liabilities are measured at fair value on a recurring basis using unobservable inputs that are classified as Level 3 inputs. Refer to Note 5, Stockholders’ Equity, for the valuation techniques and assumptions used in estimating the fair value of the derivative warrant liabilities.

  13
  

   4. Trade and other payables

      September 30, 2025

      March 31, 2025

      $ 
      $ 

      Trade payables

      459